Translate
TWO-Listed
Top companies trading on TWO, ranked by market cap.
SynbioTech Brings Taiwan's Biotech Excellence to the Global Stage with TWK10® for Muscle Performance and Healthy Aging
LAS VEGAS, Oct. 22, 2025 /PRNewswire/ -- In a field where scientific validation defines credibility, Synbio Tech Inc., a biotechnology company from Taiwan, is gaining international recognition with its proprietary probiotic Lactiplantibacillus plantarum TWK10®. The clinically proven strain, which will be featured at SupplySide Global 2025 from October 27–30 (Booth #6253F), has shown measurable benefits on muscle strength, endurance, and balance—offering a new microbiome-based approach to healthy aging and active living.
Backed by over a decade of research, TWK10® has been evaluated in peer-reviewed human clinical studies, demonstrating proven benefits in both active individuals and older adults. Clinical findings show that TWK10 boosts endurance performance by 20-40% and increases muscle mass by 0.5-1 kg, while improving overall strength, recovery, and mobility across life stages. One of these landmark studies was recognized by Wiley as a "Top Cited Article," underscoring TWK10®'s scientific impact and its growing influence in gut–muscle axis research.
TWK10® has earned strong credibility and recognition across global regulatory frameworks, including U.S. GRAS Self-Affirmed status, Korea's Health Functional Food approval, Taiwan's Health Food certification with an anti-fatigue claim, Malaysia's MAL registration, and Thailand's probiotic listing.
The recent Japan FFC authorization marks another milestone, positioning TWK10® among the most clinically and regulatorily validated probiotics for muscle health worldwide. Together with a growing portfolio of real-world data, these achievements reinforce SynbioTech's reputation as a science-driven innovator delivering microbiome-based health solutions through probiotics and postbiotics.
"For SynbioTech, it's more than a product story—it's about proving how microbiome science can truly enhance daily life," said Chuan-Hsien Yang, Chief Operating Officer at SynbioTech. "TWK10® is the result of years of research that bridge traditional fermentation knowledge from Taiwan with modern clinical science."
SynbioTech continues to expand its global partnerships and research collaborations, reflecting a broader vision to connect Asian innovation with global health markets and empower people to live healthier through microbiome science.
About Synbio Tech Inc.
Founded in 2000, Synbio Tech is a global biotechnology company specializing in probiotics, postbiotics, and microbiome-based health solutions. With over 25 years of R&D experience and a fully integrated CDMO platform, the company partners with more than 600 brands across 35 countries to deliver "From Strain to Solution" innovations that change lives with probiotics.
www.synbiotech.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/synbiotech-brings-taiwans-biotech-excellence-to-the-global-stage-with-twk10-for-muscle-performance-and-healthy-aging-302586076.html
DISCLAIMER OF LIABILITY
6ix Inc. ("6ix") licenses software to publicly traded issuers of securities ("Issuers" and each an "Issuer") which can be used by Issuers to communicate with current and prospective investors ("Investors" and each an "Investor") on the online platform maintained by 6ix Inc. at www.6ix.com (the "Platform"). Each Issuer is solely responsible for all content relating to the Issuer on the 6ix Platform, including without limitation all investor summits presented by the Issuer and all summary information about the Issuer on the 6ix Platform.
All content provided on the 6ix Platform is for informational and educational purposes only and should not be construed as investment advice or an offer or solicitation in respect to any products or services. The content presented on the 6ix Platform should not be used as the basis for any investment decision, and does not purport to provide any legal, tax or accounting advice. There are inherent risks involved with investing in Issuers, as set out in the public disclosure record of each Issuer. Issuers are not responsible for revising or updating any information that they present on the 6ix Platform.
Investors should refer to the continuous disclosure documents filed by each Issuer under applicable securities laws, including risk factors and warnings regarding "forward looking information". Issuers are solely responsible for compliance with applicable securities laws, and 6ix makes no representations and provides no assurances to Investors regarding the accuracy or truthfulness of information presented by Issuers on the 6ix Platform or in their public disclosure records.
6ix is not licensed to trade, deal or advise in securities in any jurisdiction. 6ix does not recommend or endorse any Issuer on the 6ix Platform, nor does 6ix verify the accuracy of any information presented by Issuers to Investors on the 6ix Platform or in their public disclosure records. 6ix's sole responsibility as the operator of the 6ix Platform is to provide software to Issuers and Investors through which Issuers and Investors communicate directly with each other without any intermediation or intervention by 6ix other than in respect of technical, logistical or advertising and marketing support. Issuers pay 6ix a licensing fee for use of the 6ix Platform, and 6ix may also receive payment from Issuers to pay for advertising on third-party websites. 6ix and its principals may make and hold investments in securities of Issuers on the 6ix Platform and 6ix may offer reduced rates for its software services to Issuers in which 6ix and/or its principals are invested.
ALL CONTENT ON THE PLATFORM IS PROVIDED BY THE ISSUERS "AS IS" AND "AS AVAILABLE". 6IX DOES NOT GUARANTEE THE ACCURACY OF ITS CONTENT. BY USING THE PLATFORM, EACH INVESTOR AGREES TO ACCEPT ANY RISKS ASSOCIATED WITH THE USE OF THE PLATFORM AND ACKNOWLEDGES THAT 6IX IS NOT RESPONSIBLE FOR ANY CONTENT PRESENTED BY OR RELATING TO ISSUERS ON THE PLATFORM.
6IX DOES NOT WARRANT THAT THE PROVISION OF INFORMATION BY ISSUERS ON THE PLATFORM WILL BE ERROR-FREE, TIMELY, COMPLETE OR ACCURATE. USE OF THE PLATFORM AND RELIANCE THEREON IS AT INVESTOR'S SOLE RISK. 6IX WILL NOT BE IN ANY WAY BE LIABLE TO ANY INVESTOR OR ISSUER OR ANY OTHER ENTITY OR PERSON FOR ANY INACCURACIES, ERRORS, OMISSIONS, DELAYS, DAMAGES, CLAIMS, LIABILITIES OR LOSSES, REGARDLESS OF CAUSE, IN OR ARISING FROM THE USE OF THE PLATFORM.
IN NO EVENT WILL 6IX BE LIABLE FOR ANY DAMAGES, INCLUDING WITHOUT LIMITATION DIRECT OR INDIRECT, SPECIAL, INCIDENTAL, OR CONSEQUENTIAL DAMAGES, LOSSES OR EXPENSES ARISING IN CONNECTION WITH THE USE OF THE PLATFORM BY INVESTORS AND/OR ISSUERS EVEN IF 6IX IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES, LOSSES OR EXPENSES. FURTHER, 6IX SHALL NOT BE LIABLE IN ANY MANNER FOR THE PRODUCT OR SERVICES OF ANYONE WHO REDISTRIBUTES THE INFORMATION PROVIDED ON THE PLATFORM, AND SUCH REDISTRIBUTION IS EXPRESSLY PROHIBITED.